WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 13, Issue 1, 349-376. Review Article ISSN 2277–7105

DIABETIC RETINOPATHY: A SIGHT-THREATENING COMPLICATION OF DIABETES MELLITUS

Nagesh B. Swami*, Dr. Gajanan S. Sanap

Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri, Chhatrapati Sambhajinagar 431111.

Article Received on
15 November 2023,

Revised on 05 Dec. 2023,
Accepted on 26 Dec. 2023

DOI: 10.20959/wjpr20241-30684

***Corresponding Author**
Nagesh B. Swami
Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Pathri, Chhatrapati Sambhajinagar 431111.

ABSTRACT

Diabetes mellitus is a private medical term pertaining to metabolic conditions associated with hyperglycaemia, caused by partial or complete insulin insufficiency, leading to microvascular issues. Diabetes is a condition characterized by unseasonable atherosclerosis and hyperglycaemia, affecting a significant number of cases. The frequencies of diabetes for all age- groups worldwide was estimated to be 2.8 in 2000 and 4.4 in 2030. Diabetes occurs when blood sugar situations are high due to shy insulin product or indecorous body response to insulin goods. Long- term diabetes, whether T1D or T2D, can lead to macrovascular complications like supplemental roadway complaint, nephropathy, and retinopathy, affecting the eyes, feathers, and supplemental jitters, performing in 70 casualties. Diabetic retinopathy(DR), a current condition in grown-ups progressed 20- 64 with diabetes, is a significant contributor to blurred vision. During the original two decades of diabetes, nearly all type 1 and type 2 cases parade retinopathy. Diabetic retinopathy is a condition performing in vision loss due to colourful mechanisms. Macular edema or capillary nonperfusion can affect in a reduction in central vision. The thing of this exploration was to determine the effect of diabetic retinopathy in India, both nationally and regionally.

KEYWORDS: Retinopathy, Atherosclerosis, Macular edema, ophthalmologist, Anti-VEGF, Photocoagulation, glycaemic control, inflammation.

1. INTRODUCTION

Diabetic Retinopathy (DR) is a microvascular complication of diabetes, primarily caused by chronic hyperglycaemia, resulting in intricate retinal biochemical and cellular changes. The most frequent complication of diabetes mellitus is up to 80% of those living with type 1 and type 2 diabetes for a duration of 20 years are affected by diabetic retinopathy, which is the main cause of blindness in the majority of nations. Retinopathy is believed to appear at least seven years prior to the official diagnosis of type 2 diabetes.[1] Each year in the United States, diabetic retinopathy accounts for 12% of all new cases of blindness. It is also the leading cause of blindness in people aged 20 to 64 yrs. In addition, Improved diabetes education and screening initiatives have expedited the identification and treatment of individuals at high risk for diabetes. The global number of individuals with diabetes is predicted to rise significantly, from 382 million in 2013 to 592 million by 2035.[2,3]

According to the (WHO) prediction India to become a major hub for diabetics, with nearly 80 million cases expected by 2030, up from 18 million in 1995.[4] DR is a leading cause of blindness in women during their childbearing years, and pregnancy increases the short-term risk of diabetic retinopathy progression. In the 1950s, understanding diabetic retinopathy's pathophysiology is crucial for developing new therapeutic approaches. Current treatments include vitrectomy, intravitreal anti-VEGF injections, and laser photocoagulation. Tight glycaemic control, early diagnosis, and diabetes care are essential for preventing or delaying diabetic retinopathy progression. Future targeted therapeutics may be enabled by studying the molecular and cellular mechanisms. This manuscript explores the pathophysiology of diabetic retinopathy, its epidemiology in the Indian population, and screening recommendations for paediatric populations, focusing on preventing vision loss, treatment, and upcoming treatments and screening methods suitable for the paediatric population.



To lower the risk of diabetic retinopathy, people with diabetes should control their blood pressure, cholesterol, and sugar levels. Frequent examinations of the eyes by an ophthalmologist or optometrist are essential for early detection and management. Treatment options for diabetic retinopathy include intravitreal injections, laser therapy, and vitrectomy surgery. To maintain vision and lessen the impacts of blindness, prevention, early detection, and treatment is crucial. Here, we examine the literature for Pathophysiology, risk factors, progression, management, recommendations and treatment guidelines for those individuals who suffer from Diabetic Retinopathy (DR).

2. PATHOPHYSIOLOGY

Understanding diabetic retinopathy's pathophysiology is crucial for developing new therapeutic approaches. Current treatments include vitrectomy, intravitreal anti-VEGF injections, and laser photocoagulation. Tight glycaemic control, early diagnosis, and diabetes care are essential for preventing or delaying diabetic retinopathy progression. Future targeted therapeutics may be enabled by studying the molecular and cellular mechanisms. This manuscript explores the pathophysiology of diabetic retinopathy, its epidemiology in Indian population, and screening recommendations for paediatric populations, focusing on preventing vision loss, treatment, and upcoming treatments and screening methods suitable for the paediatric population.

The structure and function of mouse retinas can be monitored longitudinally by ultra-wide-field scanning laser Ophthalmoscopy. (It is a medical device used to examine the back part of the eye). The (DCCT) was established with the purpose of evaluating the glucose hypothesis and figuring out whether type 1 diabetes problems may be prevented or eliminated.[5] Diabetic retinopathy is a neurovascular complication of type 1 and type 2 diabetes, influenced by diabetes duration and glycaemic control. A meta-analysis of 35 studies from 1980 to 2008 predicted that around 35.4% and 7.5% of patients worldwide have proliferative diabetic retinopathy.[6]

- **Due to the several mechanism diabetic retinopathies influences the loss of vision,**

1. Macular oedema, a condition characterized by increased vascular permeability or capillary nonperfusion, can potentially hinder central vision.
2. The tractional retinal detachment caused by the new blood vessels of PDR and contraction of the surrounding fibrous tissue may lead to irreversible vision loss.

3. The vision may be affected by the new blood vessels bleeding, and also by the additional complications of pre-retinal or vitreous haemorrhage.

One of the most significant mediators involved in the pathogenesis of diabetic retinopathy (DR) is vascular endothelial growth factor (VEGF). Abnormal production and release of VEGF lead to vascular endothelial cell proliferation, migration, and increased vascular permeability.[7] VEGF, a group of isoforms including PGF (placental growth factor), VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, is a significant pathogenic factor in DR, with the first isoform being the most significant. VEGF-A3 and the members in its family are well-known regulators of angiogenesis and lymph angiogenesis.

VEGF binding sites are located on glomerular endothelial cells, while visceral epithelial cells express VEGF highly. VEGF may play a crucial role in the formation and maintenance of fenestrations in glomerular capillary endothelial cells.[8] Circulating endothelial cell precursors may play a crucial role in the creation of new blood vessels.[9] VEGF was identified as a key factor in regulating retinal neovascularization and disruption of the blood-retinal barrier in diabetic retinal disease (DR).

How Diabetes Can Affect the Eyes

Diabetes is a major cause of vision loss and blindness in adults, affecting the eyes significantly. Diabetic eye disease, a condition resulting from diabetes, can impact the eyes in various ways. Diabetic Retinopathy, diabetic macular Oedema (DME), cataracts, glaucoma. Individuals with diabetes should take certain measures to prevent or manage the impact of diabetes on their eyes. To manage diabetes, follow doctor's recommendations for food, exercise, and medication. Get regular eye exams, including dilated tests, and control blood pressure and cholesterol. If diabetic retinopathy is found, follow prescribed treatments like laser therapy, injections, or surgery to prevent vision loss and control the condition.



Fig. role of VGEF in diabetic retinopathy.

3. DIABETIC RETINOPATHY IN INDIA

New National estimates for diabetes and other (NCD). In 2021, 315 million Indians had excessive hypertension, 254 million had obesity, 351 million had abdominal fat, 101 million people had diabetes, 136 had prediabetes, 185 had high LDL cholesterol, and 213 million peoples had hypercholesterolemia.[10] According to the United Kingdom Prospective Diabetes Study (UKPDS).[11] Since 1945, the incidence of diabetes has been increasing at a rate of double every 20 years.[11-12] Studies on diabetic retinopathy have been conducted in the USA and Europe to analyse its development and progression.[13] The number of individuals with diabetic retinopathy in the US general population aged 40 and older.[14] One-third of legal blindness cases in the older-onset group, characterized by common eye diseases, were caused by diabetic retinopathy. According to Diabetes Control and Complications Trial (DCCT), study in 1993,[15] In type 1 diabetes, intensive glycaemic control, or controlling blood sugar levels as close to normal as possible, reduces the development and progression of microvascular problems such retinopathy, nephropathy, and neuropathy. India has seen a steady rise in the prevalence of diabetes, mostly as a result of urbanization, changing lifestyles, and genetic predisposition. Millions of individuals in India are thought to have diabetes, and a significant number of them are thought to be at risk for developing diabetic retinopathy.

4. STAGES OF DIABETIC RETINOPATHY

4.1 Stage 1: - Mild Non-proliferative diabetic retinopathy

The early stage of diabetic retinopathy is distinguished by minute swellings or bulges in the retina's blood vessels. These swollen spots are referred to as microaneurysms, which can cause small fluid leaks into the retina, causing the macula to expand, but often without

apparent symptoms. Patients should undergo a dilated eye exam every 12 months, as there is a 5% chance that mild NPDR will transition into PDR within a year. Referrals to a retina specialist are not necessary for patients with moderate NPDR until DME is suspected or confirmed. It is crucial to educate patients, especially those recently diagnosed with diabetes, about the signs of MAs, which indicate early end organ damage, and the potential effects of the disease. Encourage monitoring of nutrition and blood sugar levels, providing a detailed report to inform the patient's PCP and/or endocrinologist, enabling informed treatment decisions.



4.2 Stage 2: - Moderate Non-proliferative diabetic retinopathy

The next stage of diabetic retinopathy is characterized by damage to some of the retinal blood vessels, which causes blood and fluid to leak into the retinal tissue. Non-proliferative diabetic retinopathy (NPDR) is a condition where the walls of blood vessels in the retina weaken, causing tiny bulges and leaks of fluid and blood. Larger vessels may also dilate and become irregular, progressing from mild to severe. Loss of vision may result from this fluid. Macular edema, a fluid accumulation in the macula, can cause vision impairment due to injury to retinal blood vessels, necessitating treatment to prevent irreversible vision loss. Every 6 to 8 months, patients with moderate NPDR should be examined.[16-17] The risk of developing proliferative diabetic retinopathy (PDR) within one year is between 12% and 27%.[17] In this stage the macula's tiny blood vessels enlarge, obstructing retinal blood supply and prevent nutrient uptake. Accumulation of blood or fluids results in blurred vision.



4.3 Stage 3: -Severe non-proliferative diabetic retinopathy

Improper diabetes management can lead to increased damage and blockage of blood vessels, resulting in more fluid leakage into the retina, causing a more severe impact on vision. At this stage, blood vessels become blocked, causing retinas to receive less blood, leading to scar tissue formation and the need for new blood vessels. In this stage Macular ischemia is a condition where blood vessels close completely, leading to blurry vision and dark spots called "floaters." If you reach this stage, your vision may be significantly lost, but treatment can potentially stop it, but it's unlikely to return if you've already lost some. Proliferative diabetic retinopathy is a severe form of diabetic retinopathy that results in the formation of new, aberrant blood vessels in the retina, filled with vitreous humour, which are brittle and can burst, as injured blood vessels seal off.

4.4 Stage 4:- Proliferative diabetic retinopathy

PDR, a condition characterized by the development of new, delicate blood vessels in the retina or the presence of blood in the vitreous cavity, is its most advanced stage. At this stage of the disease, new blood vessels in the retina develop, leading to the formation of scar tissue and retinal detachment. This detached retina can cause blurriness, a smaller field of vision, and even total blindness. These individuals need to be referred right away to a retina specialist for additional examinations and care. Laser pans retinal photocoagulation is

typically used to treat peripheral neovascularization. Patients with this retina conditions require monthly follow-ups by a retina expert until their condition stabilizes, then may be seen every six to twelve months.[16] Proliferative diabetic retinopathy is a severe form of diabetic retinopathy that results in the formation of new, aberrant blood vessels in the retina, filled with vitreous humour, which are brittle and can burst, as injured blood vessels seal off.

5. DIABETIC RETINOPATHY IN PREGNANCY

Diabetic retinopathy significantly affects women during childbearing years, with pregnancy increasing the short-term risk of progression.[18] Pregnancy-related DR management faces challenges like rapid progression, logistical issues, and contraindication of new treatments due to fatal risks. Pregnancy is a significant risk factor for the progression of DR, independent of other factors.[19] Treatment Considerations: Treatment options for diabetic retinopathy during pregnancy may differ from standard treatments due to potential risks to the developing foetus. Therefore, the timing and type of treatment will be carefully considered by healthcare providers.

Pregnant women with diabetes should have regular eye examinations by an eye specialist, such as an ophthalmologist or optometrist, before conception and during pregnancy. These exams help monitor the status of diabetic retinopathy and determine the need for any interventions. During pregnancy, several factors can contribute to the increased risk of diabetic retinopathy. Such as Blood Pressure, Blood Sugar Level, Hormonal Changes, Fluid Retention.[20]

Why does pregnancy cause retinopathy?

Although pregnancy does not cause retinopathy directly, it can worsen and speed up the development of diabetic retinopathy in women who already have the disease. Diabetes-

related high blood sugar levels are the main risk factor for the onset and evolution of diabetic retinopathy, which is predominantly a consequence of diabetes.

Hormonal changes during pregnancy, including increased plasma levels of human placental lactogen, oestrogen, and progesterone, may contribute to the progression of retinopathy.

Pregnancy-induced physiological changes, including metabolic, vascular, immunologic, and hormonal changes, can worsen DR and potentially lead to permanent visual loss if not addressed promptly.

Pregnancy-related fluid retention can lead to elevated intraocular pressure in certain women, potentially affecting the retina's fragile blood vessels.

6. CAUSES OF DIABETIC RETINOPATHY

6.1 Uncontrolled Blood Sugar Levels- Diabetes causes high blood sugar levels, damaging the retina, the eye's light-detecting part, and causing damage to blood vessels throughout the body. The Diabetes Control and Complications Trial found that strict glucose control in individuals with type 1 diabetes reduced the incidence and progression of diabetic retinopathy.[21,22] Diabetic retinopathy is a condition characterized by persistently high blood sugar levels, which damage the retina's tiny blood vessels, responsible for the light-sensitive tissue at the rear of the eye.[23] The shape and functionality of the retinal blood vessels are altered biochemically by elevated glucose levels. The microvasculature, especially the small blood vessels called capillaries that supply the retina, is harmed by persistent hyperglycaemia, and formation of AGEs due to prolonged exposure to high glucose contributes to vessel damage and inflammation.

6.2 High Blood Pressure and Cholesterol- Elevated blood pressure and cholesterol levels can worsen the condition and increase the risk of complications. cholesterol and triglycerides (dyslipidaemia) contribute to vascular complications such as Reduced blood flow exacerbates retinal ischemia, a condition where tissues don't receive enough oxygen due to Impaired Blood Flow. High lipid levels contribute to atherosclerosis, narrowing and hardening of blood vessels, including those in the retina. Hypertensive retinopathy is a medical condition characterized by retinal damage due to high blood pressure. It occurs as the existing high blood pressure causes changes to the microvasculature of the retina.

6.3 Duration and Type of Diabetes- The duration and the type of diabetes plays an imp role in DR. The longer you have diabetes and the less controlled your blood sugar is, the more likely you are to develop the retinopathy, over time, the cumulative impact of prolonged exposure to high blood sugar levels heightens the risk of retinal damage.

7. SIGNS AND SYMPTOMS OF DR

Diabetic retinopathy typically doesn't appear in its early stages due to its lack of obvious symptoms until it's more advanced. The condition often develops gradually and may not cause noticeable symptoms in the early stages. No Early Symptoms (Non-Proliferative Diabetic Retinopathy - NPDR): In the early stages, there may be no noticeable symptoms. This is why regular eye exams are crucial for early detection, especially for individuals with diabetes. When diabetic retinopathy worsens, it may manifest as various symptoms and indicators.

1) Mild to Severe Blurred Vision: As the condition advances, blurred vision can occur. Initially, it may come and go, but it can become more persistent over time.
2) Floaters: Tiny specks or spots that float across your field of vision may be present. These are caused by the presence of blood or other fluids leaking into the vitreous humour, the gel-like substance that fills the centre of the eye.
3) Dark or Empty Areas in Vision (Scotomas): Dark spots or areas of vision loss may develop as a result of damage to the blood vessels and the accumulation of blood or fluid in the retina.
4) Impaired Colour Vision: Colours may appear less vibrant or may seem faded.
5) Difficulty Perceiving Contrast: The ability to distinguish between shades of colour and brightness may be reduced.
6) Vision Fluctuations: Vision may vary throughout the day, especially if blood sugar levels are poorly controlled.
7) Vision Loss: In the advanced stages of diabetic retinopathy, significant vision loss or blindness can occur.

It's crucial for individuals with diabetes to undergo regular eye exams, at least annually, to monitor for diabetic retinopathy and other eye-related complications. Early detection and intervention are essential in managing diabetic retinopathy and preventing vision loss. Additionally, maintaining good blood sugar control, controlling blood pressure, and leading a

healthy lifestyle can contribute to overall eye health in individuals with diabetes. If you notice any changes in your vision, it's important to seek prompt medical attention.

8. GENETIC CONNECTION WITH RETINOPATHY?

While diabetes itself has a significant genetic component, and the risk of developing diabetic retinopathy is strongly associated with the duration and severity of diabetes, there is also evidence suggesting a genetic predisposition to diabetic retinopathy. The genetic factors can influence an individual's susceptibility to the condition and the rate at which it progresses. There has been much research on the significance of hereditary variables in diabetic retinopathy, but no clear evidence of a genetic component has been found.[24] Research revealed that the pathophysiology of diabetic retinopathy may be significantly influenced by hereditary or cultural variables.[25,26] A genome linkage analysis suggests that the genes causing diabetic retinopathy may differ from those causing diabetes itself, highlighting the complexity of multifactorial connections in the etiology and progression of diabetes issues.[27] The intricacy of DR poses a special difficulty due to its heterogeneous phenotypic manifestation, several linked metabolic pathways, and its status as a complication of another complicated disease, diabetes. Here are some key points regarding the genetic connection with diabetic retinopathy:

8.1 Family History: Individuals with a family history of diabetes or diabetic retinopathy may have an increased risk of developing diabetic retinopathy themselves. Genetics can play a role in determining susceptibility to diabetes and its complications. This correlation implies that proliferative retinopathy may occur as a result of familial factors as well.[28]

8.2 Candidate Genes: Researchers have identified specific genes that may be associated with an increased risk of diabetic retinopathy. These genes are involved in various processes, including inflammation, angiogenesis (the formation of new blood vessels), and the regulation of blood vessel function.[29]

- **VEGF (Vascular Endothelial Growth Factor):** VEGF, a signalling molecule, is crucial in the formation of new blood vessels, or angiogenesis, in the retina, a characteristic of diabetic retinopathy. Its role in the formation of aberrant blood vessels in the retina has been extensively studied.[30]

- **AGER (Advanced Glycosylation End Product-Specific Receptor):** The Advanced Glycosylation End Product-Specific Receptor (AGER), also known as the receptor for advanced glycation end products (RAGE), is a cell surface receptor involved in the pathogenesis of diseases like diabetic retinopathy. It responds to AGEs, which accumulate in tissues over time, particularly in the presence of diabetes.[31]

- **TNF (Tumour Necrosis Factor):** TNF, a pro-inflammatory cytokine, is crucial in the development and progression of diabetic retinopathy, a disease characterized by elevated levels of inflammatory markers, including TNF, in the retina of individuals with the condition.[32]

8.3 Polymorphisms: Certain genetic variations, known as polymorphisms, have been linked to an increased risk of diabetic retinopathy. These variations may affect how the body responds to high blood sugar levels and the damage they can cause to blood vessels in the retina.[33]

8.4 Heritability Studies: Studies on the heritability of diabetic retinopathy suggest that genetic factors contribute to the development of the condition. Heritability is a measure of how much of the variation in a trait can be attributed to genetic factors. Family and twin studies are being conducted to evaluate the heritability of retinopathy, aiming to understand the extent of genetic variability in the condition.[34]

8.5 Polygenic Nature of Diabetic Retinopathy: Many different genetic variables are thought to play a role in the complicated characteristic known as diabetic retinopathy. It is probably polygenic, meaning that different genes play different roles in its growth and development.

Research has been done on genetic polymorphisms associated with vascular function, inflammation, angiogenesis, and oxidative stress.[35,36]

It's important to note that while genetics can influence the risk of developing diabetic retinopathy, environmental factors such as blood sugar control, blood pressure management, and lifestyle choices also play a crucial role. Individuals with diabetes, especially those with a family history of diabetes or diabetic retinopathy, should be vigilant about managing their diabetes and undergo regular eye exams to detect and manage diabetic retinopathy early. As research in genetics and ophthalmology continues, more insights into the specific genetic

factors influencing diabetic retinopathy may emerge, potentially leading to improved risk assessment and personalized approaches to treatment and prevention.

9. DIAGNOSIS STRATEGIES FOR DIABETIC RETINOPATHY

An eye consequence of diabetes is called diabetic retinopathy. Early diagnosis and management of diabetic retinopathy is crucial in preventing visual loss. A thorough eye examination, a review of medical history, and several imaging tests are usually used in the diagnosing process. Clinical diagnosis of diabetic retinopathy (DR) is made by direct inspection of the retinal fundus or by using imaging methods such optical coherence tomography or fundus photography. Numerous common grading schemes for diabetic retinopathy exist, including the Early Treatment Diabetic Retinopathy Study (ETDRS).[37]

Multiple layers are used by ETDRS to differentiate finely detailed DR features.[38] All seven retinal fundus Fields of View are graded using this method (FOV).[39] Despite being the gold standard, ETDRS is not always utilized due to technological restrictions and implementation complexity. An alternate grading system that is widely recognized in both clinical and Computer-Aided Diagnosis (CAD) contexts is the International Clinical Diabetic Retinopathy (ICDR) scale.[40,41]

9.1 Dilated Eye Exam: A dilated eye exam's main goal is to assess the retina, optic nerve, and blood vessels, which are located in the inner part of the eye. This test aids in the detection of a number of eye disorders and illnesses, including glaucoma, macular degeneration, and diabetic retinopathy.[42]

9.2 Fluorescein Angiography: The main purposes of it are to assess and identify different kinds of retinopathy, macular degeneration, and abnormalities of the vessels in the eyes. offers comprehensive details on the composition of blood vessels, leaks, and alterations in blood flow inside the choroid and retina.[43]

9.3 Optical Coherence Tomography (OCT): A non-invasive imaging technique called optical coherence tomography (OCT) produces high-resolution, cross-sectional pictures of the retina, optic nerve, and other eye components. It enables medical practitioners to detect different eye problems and evaluate the health of the eye by using light waves to produce detailed, three-dimensional pictures.[44]

9.4 Retinal Photography: A diagnostic imaging method called fundus photography, or retinal photography, is used to take detailed pictures of the retina, optic nerve, and blood vessels in the back of the eye. These pictures aid medical practitioners in the assessment and monitoring of different eye problems.[45,46]

9.5 Tonometry: Intraocular pressure (IOP), or intraocular pressure, is measured by tonometry, a diagnostic technique. There is a correlation between elevated intraocular pressure and eye disorders like glaucoma. Tonometry is a routine process used in eye exams to measure intraocular pressure and determine glaucoma risk.[47]

9.6 Visual Acuity Testing: A common practice used to evaluate a person's eyesight clarity and sharpness is visual acuity testing. This exam assesses the eye's capacity to discern shapes and details at a certain distance**.**[48] Visual acuity tests are primarily used to assess visual acuity and detect abnormalities in the eyes that may indicate refractive problems. It is a necessary part of regular ocular exams.[49]

9.7 Artificial Intelligence (AI) in Diabetic Retinopathy Screening: Artificial Intelligence (AI) technologies are being developed to help in diabetic retinopathy early identification and monitoring.[50] Artificial Intelligence (AI) screening for diabetic retinopathy uses machine learning algorithms to automatically detect diabetic retinopathy symptoms by analysing retinal pictures. This device has demonstrated significant potential to enhance the effectiveness and availability of diabetic retinopathy screening.[51,52]

9.8 Ophthalmoscopy: The most popular method for checking for diabetic retinopathy is ophthalmoscopy. However, compared to stereoscopic seven-field colour photography, undilated ophthalmoscopy—especially when performed by non-eye care providers—has inadequate sensitivity.[53,54] Direct ophthalmoscopy performed by non-ophthalmologists under standard clinical settings has a 50% sensitivity for proliferative retinopathy identification.[55]

It is currently unknown what the molecular causes of diabetic retinopathy are, including whether the (pro)renin receptor plays a role in the activation of the retinal renin-angiotensin system (RAS). More specialized treatments and the identification of new pharmacological targets may result from these investigations.[56] Lack of medical resources has delayed the identification and treatment of diabetic retinopathy, despite advancements in management.

An automated screening program and more sensitive biomarkers are crucial for early detection and reduced blindness.[57]

10. TREATMENT OF DIABETIC RETINOPATHY

The goal of treatment is to halt or stop the progression of the diabetic retinopathy, which mostly depends on the kind and severity of your condition. Understanding disease-causing pathways and implementing prevention strategies are crucial to prevent their progression.[58] Diabetes retinopathy develops as patients struggle to maintain blood glucose and blood pressure, which results in the progression of DR.[59,60] Chronic renal failure, long-term diabetes, higher HBA1c levels, and hypertension are all considered to be risk factors for the development of DR.[61,62] DR was a major contributor to blindness and visual impairment in worldwide, but photocoagulation gained widespread use due to lack of effective alternatives. The Diabetic Retinopathy Study (DRS) 1971-75, demonstrated that scatter laser photocoagulation effectively reduces the risk of severe visual loss.[63] The treatment aims to halt or stop the progression of diabetic retinopathy, largely based on the type and severity of the condition.

The following drugs and procedures are frequently employed in the management of diabetic retinopathy

- **Blood Sugar Control:** Keeping blood sugar levels under strict control is essential to treating diabetic retinopathy and stopping its development.[64]
- **Blood Pressure Management**: Maintaining blood pressure control is essential for preventing or delaying the development of diabetic retinopathy.[65]
- **Laser Photocoagulation:** Proliferative diabetic retinopathy is treated with laser treatment, which eliminates abnormal blood vessels and repairs defective blood vessels.[66,67]
- **Vitrectomy:** A vitrectomy may be necessary in more severe cases of tractional retinal detachment or vitreous haemorrhage in order to remove scar tissue or blood from the eye.[68]
- **Panretinal Photocoagulation (PRP):** In order to stop the formation of aberrant blood vessels in the peripheral retina, a procedure known as peripheral retina photocoagulation (PRP) uses dispersed laser burns.[69] PRP involves applying numerous lasers burns to the peripheral areas of the retina. These burns destroy the peripheral areas of the retina, reducing the oxygen demand and stimulating the regression of abnormal blood vessels.[70]

- **Neuroprotective Agents:** A number of research investigate the possibility of using neuroprotective drugs to either stop or delay the development of diabetic retinopathy.[71]
- **Telemedicine and Screening Programs:** Early detection of diabetic retinopathy is becoming more common through telemedicine and screening programs, resulting in immediate treatments.[72]
- **Artificial Intelligence (AI) in Diabetic Retinopathy Screening:** Artificial Intelligence (AI) technologies are being developed to help in diabetic retinopathy early identification and monitoring.[73]
- **Stem Cell Therapy:** Research on stem cell treatment for diabetic retinopathy is ongoing, and a number of studies have looked into the possibility of using stem cells to heal retinal damage brought on by diabetes. Notably, this subject is still in the experimental stage; additional study is required before stem cell therapy becomes a regular treatment for diabetic retinopathy, even if preclinical studies and certain early-phase clinical trials show promise.[74]
- **Intravitreal Injections:** Dexamethasone implants are one type of intravitreal implant that can be used to deliver steroids continuously in order to lower inflammation and macular edema.[75]
- **Anti-VEGF medications:** These medications are frequently used to treat diabetic macular edema (DME), a side effect of diabetic retinopathy. They function by preventing the activity of VEGF, which encourages the formation of aberrant blood vessels and results in fluid leaking in the retina.

Anti-VEGF treatment is usually administered through intravitreal injections into the eye. It typically involves a series of injections over several months, as the effects of a single injection may not be long-lasting. Individuals with diabetic macular oedema exhibit significantly higher levels of VEGF in their vitreous compared to those without diabetic eye conditions.[76] The injection schedule and frequency will be determined by the treating ophthalmologist.

Typical anti-VEGF medications include

1) **Ranibizumab (Lucentis): -** Ranibizumab works by inhibiting the action of VEGF, a protein that plays a crucial role in stimulating the growth of abnormal blood vessels and increasing vascular permeability in the eye.[77] By blocking VEGF, ranibizumab helps reduce the growth of these abnormal blood vessels and the leakage of fluid, ultimately

improving or stabilizing vision. With a half-life of 3 days, ranibizumab (Lucentis) exits all ocular compartments; after two days, 50% of the medication is in the bloodstream.[78] Ranibizumab is administered via intravitreal injections, which means it is injected directly into the vitreous humour (the jelly-like substance in the centre of the eye) using a very fine needle. This method allows for the medication to be delivered directly to the site of action. The study evaluated the effect of Ranibizumab on vascular leakage using a modified Miles's Test.[79]

2) **Aflibercept (Eylea):** - Another anti-VEGF medication injected into the eyes. Despite not being expressly licensed for the treatment of diabetic retinopathy.
3) **Bevacizumab (Avastin):** - is occasionally used off-label for its anti-VEGF properties. Intravitreal bevacizumab injection is a valuable supplement to traditional PRP for PDR treatment, facilitating faster and more significant regress of new vasculature compared to PRP alone.[80]

Anti-VEGF medication has been shown to effectively reduce retinal neovascularization in patients with Progressive Detachment Retinopathy (PDR).[81]

- **Steroids:** - Steroids can aid in reducing swelling and inflammation in the retina. The pathophysiology of diabetic retinopathy is significantly influenced by inflammation.[82,83]
- **Dexamethasone implants:** - These are also known as "Ozurdex," are biodegradable implants that are put into the eye and gradually release dexamethasone to treat inflammation.
- **Fluocinolone Acetonide Implants (Iluvien):** A tiny implant placed in the eye that releases fluocinolone acetonide over time.
- **Laser Therapy:** Retinal laser therapy is utilized for managing conditions in clinics and operating rooms, including complex conditions like tractional retinal detachments in diabetic retinopathy.[84] Laser treatment for diabetic retinal problems can significantly reduce visual loss if used promptly, but it must be combined with optimizing other risk factors for disease progression, such as controlling blood pressure and blood glucose levels.[85,86] A significant portion of the visual impairment brought on by diabetic retinopathy is due to macular edema.[87] To prevent serious vision loss, proper and timely treatment is crucial.
- **Focal Laser Photocoagulation:**- Focal laser therapy can stabilize or enhance central vision in diabetic macular edema patients, but may not completely restore normal vision.

Laser photocoagulation significantly reduced the likelihood of moderate visual acuity loss in eyes with approximately 50% three years post-procedure.[88,89]

- **Corticosteroids:-** Corticosteroids can help reduce inflammation and swelling in the macula, which can be beneficial in managing DME.[90] It's important to note that while corticosteroids can be effective in reducing inflammation and edema associated with diabetic retinopathy, they are not typically used as a first-line treatment. Corticosteroids have potential side effects, including increased intraocular pressure and cataract formation, which must be carefully monitored when using these medications.[68]
- **Nutritional Supplements:-** Nutritional supplements are occasionally used in the treatment of diabetic retinopathy, often alongside other therapeutic measures and dietary changes, as a supplement rather than a standalone treatment.
- **Antioxidant Vitamins:-** Vitamins with antioxidant properties, such as vitamin C, vitamin E, and beta-carotene, can assist in protecting the eyes from oxidative damage.[91,92] Similar ideas have been used to diabetic retinopathy.[78] The Age-Related Eye Disease Study (AREDS)[93] proposed that antioxidant vitamins might have a positive impact on eye health.
- **Zinc:** -Zinc, along with antioxidant vitamins, is often found in nutritional supplements to promote retina health and prevent retinopathy, but excessive use can have negative effects.[94]
- **Fenofibrate:** The impact of fenofibrate on the development of diabetic retinopathy in people with type 2 diabetes was examined in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial. The purpose of the experiment was to investigate the potential benefits of fenofibrate, a drug that is frequently used to decrease cholesterol, for diabetic retinopathy.[95]
- **Tyrosine Kinase Inhibitors:** Tyrosine kinase inhibitors inhibit certain enzymes involved in angiogenesis and cell signalling.[96]
- **Angiopoietin Inhibitors:** Angiopoietins have a role in the development of blood vessels. Angiogenesis may be impacted by blocking angiopoietin signalling.[97]
- **Combination Therapies:** Clinical studies and research have shown interest in combination treatments for diabetic retinopathy. Here are a few possible combo treatments

i) **Laser therapy combined with anti-VEGF:** Laser treatment in addition to anti-VEGF medications to treat abnormal blood vessel growth and vascular leakage.[98] Anti-VEGF

medications block VEGF's effects, which are essential for the development of abnormal blood vessels, and laser treatment can be utilized to target certain regions of the retina. This is a connection that is significant to this combo treatment.[99]

ii) **Steroid and Anti-VEGF Therapy:** combining anti-VEGF medications with intravitreal steroids to treat vascular alterations and inflammation. (100) For the treatment of a number of retinal disorders, including diabetic macular edema, the combination of steroid and anti-VEGF (vascular endothelial growth factor) therapy has been investigated. Anti-VEGF medications focus on the vascular alterations linked to diseases like diabetic retinopathy, whereas steroids, such triamcinolone acetonide, have anti-inflammatory qualities. This is a link that belongs to the combo treatment.[68]

iii) **Combination Anti-VEGF Agents:** Evaluating the benefits of mixing several anti-VEGF medications for diabetic macular edema.[101] Combination anti-VEGF (vascular endothelial growth factor) therapies have garnered attention as a means of treating retinal diseases, such as diabetic retinopathy. Combining several anti-VEGF medicines may improve therapeutic outcomes since they each may have a different mechanism of action. This is a link that is important to the comparison of anti-VEGF agents.

iv) **Steroids and Laser Therapy:** The use of steroids in conjunction with laser therapy has been investigated as a therapeutic option for a variety of retinal diseases, including diabetic retinopathy. Steroids with anti-inflammatory qualities, such as triamcinolone acetonide, are commonly utilized, whereas laser treatment is frequently employed to target specific parts of the retina, particularly in situations with proliferative diabetic retinopathy.[102]

It's crucial for individuals with diabetes to maintain good overall health and closely monitor their eye health through regular check-ups. Early detection and intervention can significantly reduce the risk of vision loss associated with diabetic retinopathy. Treatment plans are tailored to the specific needs and stage of the disease for each patient, and close collaboration with a healthcare team is essential for effective management.

CONCLUSION

In conclusion, this exploration into diabetic retinopathy has unveiled the intricate interplay between diabetes and vision health. Our examination of key findings underscores the urgency of regular eye screenings and effective blood sugar management. As we summarize the impact on retinal blood vessels and the potential consequences for vision, it becomes clear

that proactive measures are essential in the fight against diabetic retinopathy. Looking ahead, the future implications of this research are promising. Advances in technology and treatment modalities offer hope for improved outcomes. However, the real catalyst for change lies in public awareness and individual empowerment. By disseminating knowledge, advocating for regular eye check-ups, and fostering a culture of proactive health management, we can collectively reduce the prevalence and severity of diabetic retinopathy. On a personal note, delving into this subject has been both enlightening and humbling. The stories of individuals grappling with the impact of diabetic retinopathy have fueled my commitment to spreading awareness. It is my sincere hope that this work serves not only as an informative resource but also as a catalyst for positive change.

Together, we can envision a future where diabetic retinopathy is not just a concern but a preventable and manageable aspect of diabetes care.

REFERENCE

1. American Diabetes Association: All about diabetes [webpage]. Available from http://www.diabetes.org/about-diabetes. jsp. Accessed 16 January 2004.
2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract., 2014; 103(2): 137–149. Doi: 10.1016/j.diabres.2013.11.002.
3. Nanditha A, et al. Diabetes in Asia and the Pacific: Implications for the Global Epidemic. Diabetes Care, 2016; 39(3): 472–485. Doi: 10.2337/dc15-1536.
4. Rajiv Raman, MS, DNB,1 Padmaja Kumari Rani, 2009 by the American Academy of Ophthalmology Prevalence of Diabetic Retinopathy in India Doi: 10.1016/j.ophtha.2008.09.010.
5. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Diabetes Care, January, 2014; 37.
6. D Shalomon, Emily chew, Diabetic Retinopathy: A Position Statement by the American Diabetes Association Shalon https://doi.org/10.2337%2Fdc16-2641.
7. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl, 2000; 77: S113.
8. V. Eremina, M. Sood, J. Haigh, et al. Glomerular-specific alterations of VEGF-A expression led to distinct congenital and acquired renal diseases Clin Invest, 2003; 111: 707.

9. Ribatti D.Vacca A.Nico B.Roncali L. Dammacco F. Mech. Dev. Postnatal vasculogenesis, 2001; 100: 157-163.
10. India logged 31 million new diabetes patients in 2019-21: study. https://www.thehindu.com/sci-tech/health/31-million-more-indians-became-diabetic-between-2019-2021-says-study/article66949970.ece.
11. Kohner E, Stratton I, Aldington S, Holman R, Matthews D. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med., 2001; 18: 178–84.
12. Barnett T. Epidemiology, complications and costs of diabetes mellitus. In The insulin treatment of diabetes: a practical guide, Ed. Tony Barnett, London, E-map healthcare, 1998; 6–9.
13. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol, 1989; 107: 244–49.
14. The Prevalence of Diabetic Retinopathy Among Adults in the United States, ARCH OPHTHALMOL, APR., 2004; 122. https://doi.org/10.1001/archopht.122.4.552.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med., 1993; 329: 977–986.
16. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology, 2018; 125(10): 1608-1622.
17. American Optometric Association. Evidence-based Clinical Practice Guideline: Eye Care of the Patient with Diabetes Mellitus. www.aoa.org/optometrists/tools-and-resources/evidence-based-optometry/evidence-based-clinical-practice-guidlines/cpg-3--eye-care-of-the-patient-with-diabetes-mellitus. Accessed May 2, 2019.
18. A review, Julie L Morrison BOOS(Hons) MPH, Diabetic retinopathy in pregnancy: Clinical and Experimental Ophthalmology, 2016; 44: 321–334. Doi: 10.1111/ceo.12760.
19. Diabetes Control Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes Care, 2000; 23: 1084–91.
20. Diabetic Retinopathy Risk Factors https://www.news-medical.net/health/Diabetic-Retinopathy-Risk-Factors.aspx.

21. Klein R. The Diabetes Control and Complications Trial. Kertes C, ed. Clinical Trials in Ophthalmology: A Summary and Practice Guide, 1998; 49-70.
22. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev., Feb., 2009; 5(1): 3-7.
23. Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. BMJ., Feb., 12, 2009; 338: b441.
24. Schwartz, J. A., Lantis, II, J. C., Gendics, C., Fuller, A. M., Payne, W. and Ochs, D. A prospective, non-comparative, multicentre study to investigate the effect of cadexomer iodine on bioburden load and other wound characteristics in diabetic foot ulcers. Int. Wound J., 2012. Doi: 10.1111/ j.1742-481X.2012.01109.x.
25. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY, Brancati FL, Hubbard LD, Couper D. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities' study. Ophthalmology, 2002; 109(7): 1225–1234.
26. Haffner SM, Hazuda HP, Stern MP. Effect of socioeconomic status on hyperglycaemia and retinopathy levels in Mexican Americans with NIDDM. Diabetes Care., 1989; 12: 128–134.
27. Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. Diabetes, 2007; 56(4): 1167–1173.
28. Hietala K, Forsblom C, Summanen P, Groop PH, FinnDiane Study Group. Heritability of proliferative diabetic retinopathy. Diabetes, Aug. 1, 2008; 57(8): 2176-80.
29. Petrovič D. Candidate genes for proliferative diabetic retinopathy. BioMed research international, Aug. 27, 2013; 2013.
30. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med., 1994; 331(22): 1480-1487. DOI: 10.1056/NEJM199412013312203.
31. Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Bio Chem., 2002; 277(23): 20309-20315. DOI: 10.1074/jbc.M110636200.
32. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J., 2004; 18(12): 1450-1452. DOI: 10.1096/fj.04-1170fje.

33. Gong JY, Sun YH. Association of VEGF gene polymorphisms with diabetic retinopathy: a meta-analysis. PloS one, Dec. 20, 2013; 8(12): e84069.
34. Kowluru RA, Mishra M. "Genetic and Molecular Mechanisms of Diabetic Retinopathy" Current Diabetes Reviews, Aug., 2005; 1(3): 343-53. DOI: 10.2174/1573399054038743.
35. Petrovič D. "Genetics of Diabetic Retinopathy" Journal of Diabetes Research, 2013; 2013: 438453. DOI: 10.1155/2013/438453.
36. Grassi MA. "Genetics of Diabetic Retinopathy" Current Diabetes Reports, Apr, 2009; 9(2): 127-32. DOI: 10.1007/s11892-009-0022-3.
37. Early Treatment Diabetic Retinopathy Study Research Group. Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs-An Extension of the Modified Airlie House Classification: ETDRS Report Number 10. Ophthalmology, 1991; 98: 786–806. [Google Scholar].
38. Horton, M.B.; Brady, C.J.; Cavallerano, J.; Abramoff, M.; Barker, G.; Chiang, M.F.; Crockett, C.H.; Garg, S.; Karth, P.; Liu, Y.; et al. Practice Guidelines for Ocular Telehealth-Diabetic Retinopathy, Third Edition. Telemed. E-Health, 2020; 26: 495–543. [Google Scholar] [PubMed].
39. Solomon, S.D.; Goldberg, M.F. ETDRS Grading of Diabetic Retinopathy: Still the Gold Standard? Ophthalmic Res., 2019; 62: 190–195. [Google Scholar] [PubMed].
40. Wilkinson, C.; Ferris, F.; Klein, R.; Lee, P.; Agardh, C.D.; Davis, M.; Dills, D.; Kampik, A.; Pararajasegaram, R.; Verdaguer, J.T. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology, 2003; 110: 1677–1682. [Google Scholar].
41. Rajalakshmi, R.; Prathiba, V.; Arulmalar, S.; Usha, M. Review of retinal cameras for global coverage of diabetic retinopathy screening. Eye., 2021; 35: 162–172. [Google Scholar].
42. American Academy of Ophthalmology. (2019). Comprehensive Adult Medical Eye Evaluation (CPT® Code 92004-92014). Retrieved from https://www.aao.org/preferred-practice-pattern/comprehensive-adult-medical-eye-evaluation-ppp.
43. American Academy of Ophthalmology. (2019). Fluorescein Angiography (CPT® Code 92235). Retrieved from https://www.aao.org/preferred-practice-pattern/fluorescein-angiography-ppp.
44. Drexler, W., & Fujimoto, J. G. State-of-the-art retinal optical coherence tomography. Progress in Retinal and Eye Research, 2008; 27(1): 45–88. Doi: 10.1016/j.preteyeres.2007.07.005.

45. American Academy of Ophthalmology. (2019). Fundus Photography (CPT® Code 92250). Retrieved from https://www.aao.org/preferred-practice-pattern/fundus-photography-ppp.
46. National Eye Institute. (2019). Diabetic Retinopathy. Retrieved from https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy.
47. American Optometric Association. (2015). Comprehensive Adult Eye and Vision Examination. Retrieved from https://www.aoa.org/Documents/optometrists/CPG-14.pdf.
48. American Diabetes Association. Standards of Medical Care in Diabetes - 11. Microvascular Complications and Foot Care. Diabetes Care, 2022; 45(1): S168-S179. doi:10.2337/dc22-S011.
49. American Academy of Ophthalmology. (2019). Comprehensive Adult Medical Eye Evaluation (CPT® Code 92004-92014). Retrieved from https://www.aao.org/preferred-practice-pattern/comprehensive-adult-medical-eye-evaluation-ppp.
50. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ., 1998; 317(7160): 703-713. DOI: 10.1136/bmj.317.7160.703.
51. Gulshan, V., Peng, L., Coram, M., et al. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus Photographs. JAMA, 2016; 316(22): 2402–2410. DOI: 10.1001/jama.2016.17216.
52. Rajalakshmi, R.; Subashini, R.; Anjana, R.M.; Mohan, V. Automated Diabetic Retinopathy Detection in Smartphone-Based Fundus Photography Using Artificial Intelligence. Eye, 2018; 32(6): 1138–1144. DOI: 10.1038/s41433-018-0088-y.
53. Hutchinson A, McIntosh A, Peters J, O'Keeffe C, Khunti K, Baker R, Booth A: Effectiveness of screening and monitoring tests for diabetic retinopathy: a systematic review. Diabet Med., 2000; 17: 495–506.
54. Fong, D. S., Aiello, L. P., Ferris III, F. L., & Klein, R. Diabetic retinopathy. Diabetes care, 2004; 27(10): 2540-2553.
55. Sussman EJ, Tsiaras WG, Soper KA: Diagnosis of diabetic eye disease. JAMA 1982; 247: 3231–3234.
56. Kanda A, Ishida S. (Pro)renin receptor: involvement in diabetic retinopathy and development of molecular targeted therapy. J Diabetes Investig, 2019; 10: 6–17.

57. Lin, K. Y., Hsih, W. H., Lin, Y. B., Wen, C. Y., & Chang, T. J. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. Journal of diabetes investigation, 2021; 12(8): 1322-1325.
58. Mariangela Rondanelli, Clara Gasparri*, Antonella Riva,Diet and ideal food pyramid to prevent or support the treatment of diabetic retinopathy, age-related macular degeneration, and cataracts, PUBLISHED 30 May 2023 DOI 10.3389/fmed.2023.1168560.
59. Advances in the Medical Treatment of Diabetic Retinopathy RAFAEL SIMO´, MD, PHD CRISTINA HERNANDEZ, MD, PHD DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009.
60. Lachin, J.M.; White, N.H.; Hainsworth, D.P.; Sun, W.; Cleary, P.A.; Nathan, D.M. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes, 2015; 64: 631–642.
61. Schanzlin, D.J.; Jay, W.H.; Fritz, K.J.; Tripathi, R.C.; Gonen, B. Hemoglobin A1 and diabetic retinopathy. Am. J.Ophthalmol, 1979; 88: 1032–1038.
62. Associazione Medici Diabetology and Società Italiana di Diabetologia (Ed.) Standard Italiani per la Cura del Diabetes Mellito AMD-SID; Associazione Medici Diabetologi and Società Italiana di Diabetologia: Rome, Italy, 2016; Available online:http://www.siditalia.it/pdf/Standard%20di%20Cura%20AMD%20-%20SID%202018_protetto.pdf (accessed on 27 April 2018).
63. Sam E Mansour, David J Browning Keye Wong the Evolving Treatment of Diabetic Retinopathy, http://doi.org/10.2147/OPTH.S236637.
64. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med., 1993; 329(14): 977-986. DOI: 10.1056/NEJM199309303291401.
65. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology, 1991; 98(5): 766-785. DOI: 10.1016/S0161-6420(13)38013-4.
66. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol, 1985; 103(12): 1796-1806. DOI: 10.1001/archopht.1985.01050120030015.

67. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 2008; 115(9): 1447-1459. DOI: 10.1016/j.ophtha.2008.06.018.
68. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology, 1987; 94(7): 761-774. DOI: 10.1016/S0161-6420(87)33645-2.
69. Palanker DV, Blumenkranz MS, Marmor MF. Fifty years of ophthalmic laser therapy. 392 Arch Ophthalmol, Dec., 2011; 129(12): 1613-9.
70. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res., 2007; 2007: 95103. DOI: 10.1155/2007/95103.
71. Ryan M, Francis AW, Arocena L, et al. Diabetic retinopathy screening in incident diabetes mellitus and subsequent mortality. Diabetologia, 2017; 60(4): 641-648. DOI: 10.1007/s00125-016-4167-1.
72. Ting DSW, Cheung CY, Lim G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA, 2017; 318(22): 2211-2223. DOI: 10.1001/jama.2017.18152.
73. Park SS, Moisseiev E, Bauer G, Anderson JD, Grant MB, Zam A, Zawadzki RJ, Werner JS, Nolta JA. Advances in bone marrow stem cell therapy for retinal dysfunction. Prog Retin Eye Res., 2017; 56: 148-165. DOI: 10.1016/j.preteyeres.2016.11.002.
74. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology, 2014; 121(10): 1904-1914. DOI: 10.1016/j.ophtha.2014.04.024.
75. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin IIand vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol, 2002; 133: 537–543.
76. Neelakshi Bhagat, Grigorian R.A., Tutela A. Diabetic macular edema: pathogenesis and treatment. Surv. Ophthalmol, 2009; 54: 1–32. [PubMed] [Google Scholar].
77. Monica Rodriguez-Fontal*, Virgil Alfaro, John B. Ranibizumab for Diabetic Retinopathy Current Diabetes Reviews, 2009; 5(1). https://doi.org/10.2174/157339909787314239.
78. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology, 2007; 114: 2179-82.

79. Tonello M., Costa R.A., Almeida F.P. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHistudy) Acta Ophthalmol, 2008; 86: 385–389. [PubMed] [Google Scholar].
80. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology, 2006; 113: 1695–1705.
81. A. Das, S. Stroud, A. Mehta, S. Rangasamy New treatments for diabetic retinopathy 27 August 2014 https://doi.org/10.1111/dom.12384.
82. Rangasamy S, McGuire P, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol, 2012; 19: 52–59.
83. Campochiaro P, Brown DM, Pearson A et al., FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least3 years in patients with diabetic macular edema. Ophthalmology, 2012; 110: 2125–2132.
84. Everett, Lesley A., and Yannis M. Paulus. "Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema." Current diabetes reports, 21: 1-12.
85. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes, 1995; 44: 968–983.
86. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998; 317: 703–713.
87. Klein R, Klein BE, Moss SE: Visual impairment in diabetes. Ophthalmology, 1984; 91: 1–9.
88. Photocoagulation for diabetic macular edema Early Treatment Diabetic Retinopathy Study Report Number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol, Dec., 1985; 103(12): 1796–806. PMID: 2866759.
89. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation For diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol, 1985; 103: 1796–1806.
90. Uckermann O, Kutzera F, Wolf A,et al. The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signalling, 2005; 315: 1036– 1045.
91. BuringJF, Hennekens CH. In: Prasad K, ed. Nutrients in Cancer Prevention and Treatment Totowa, NJ: Humana, 1995; 223–234.

92. Sperduto RD, Ferris FL, 3rd, Kurinij N. Do we have a nutritional treatment for age-related cataract or macular degeneration? Arch Ophthalmol, 1990; 108: 1403–1405.
93. Kahn HA, Moorhead HB. Statistics on Blindness in the Model Reporting Area. 1969–1970 Washington, D.C.: USDHEW, PHS Publication No. (NIH), 1973; 73–427.
94. National Advisory Eye Council. Report of the Retinal and Choroidal Diseases Panel. Vision Research-A National Plan: 1983–1987 Bethesda, MD: U.S. Department of Health and Human Services, 1984.
95. Newsome DA, Swartz M, Leone NC, et al. Oral zinc in macular degeneration. Arch Ophthalmol, 1988; 106: 192–198.
96. Keech AC, Mitchell P, Summanen PA, et al.; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet., 2007; 370(9600): 1687-1697. DOI: 10.1016/S0140-6736(07)61607-9.
97. Campochiaro PA, Khanani A, Singer M, et al. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression. Ophthalmology, 2016; 123(8): 1722-1730. DOI: 10.1016/j.ophtha.2016.04.014.
98. Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med., 2016; 8(11): 1265-1288. DOI: 10.15252/emmm.201606319.
99. Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: A systematic review and meta-analysis. Retina, 2015; 35(10): 1931-1942. DOI: 10.1097/IAE.0000000000000757.
100. Gross JG, Glassman AR, Jampol LM, et al.; Writing Committee for the Diabetic Retinopathy Clinical Research Network. JAMA., 2015; 314(20): 2137-2146. DOI:10.1001/jama.2015.15217.
101. Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology, 2016; 123(6): 1351-1359. DOI: 10.1016/j.ophtha.2016.02.022.
102. Diabetic Retinopathy Clinical Research Network. Ophthalmology, 2007; 114(10): 1860-1867. DOI: 10.1016/j.ophtha.2007.06.042.